Mildronate-efficacy and safety in treatment for chronic coronary heart Disease (stable angina) II - MILSS II

JSC Grindeks0 个研究点目标入组 300 人开始时间: 2005年1月6日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Written informed consent. Age over 18 years. At least 3 months history of stable effort angina relieved by rest or sublingual nitroglycerin. Coronary heart disease with severity of CCS class II-III. Myocardial ischaemia with typical ST - changes as the limiting factor of exercise in bicycle ergometry.
•Are the trial subjects under 18?
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Known intolerance of mildronate or its ingredients. Inability to perform bicycle ergometry test. Myocardial infarction, stroke or unstable angina within 3 months before randomisation. Hemodynamically significant valvular heart disease. Sustained ventricular tachycardia, supraventricular tachycardia, ventricular flutter or fibrillation within 3 months prior the study.

发起方